Overview

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.
Phase:
Phase 3
Details
Lead Sponsor:
Xigen SA